The Consensus Molecular Subtypes is a predictive biomarker for anti-EGFR antibody effect in metastatic colorectal cancer

被引：0
|
作者：
Okita, Akira [1 ]
Takahashi, Shin [1 ]
Ouchi, Kota [1 ]
Yamada, Yasuhide
Takahashi, Masanobu [1 ]
Ishioka, Chikashi [1 ]
机构：
[1] Tohoku Univ, Dept Cli Onco, IDAC, Sendai, Miyagi, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
Colorectal cancer; CMS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2212
引用
收藏
页码：673 / 673
页数：1
相关论文
共 50 条
  • [31] Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
    Martins, Marta
    Mansinho, Andre
    Cruz-Duarte, Raquel
    Martins, Soraia Lobo
    Costa, Luis
    TARGETED THERAPY OF COLORECTAL CANCER SUBTYPES, 2018, 1110 : 113 - 131
  • [32] EGFR and KRAS mutations during anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer: Clinically relevant?
    Karayan-Tapon, Lucie
    Ferru, Aurelie
    Cortes, Ulrich
    Villalva, Claire
    Tourani, Jean Marc
    Silvain, Christine
    Levillain, Pierre
    Tougeron, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Personalized Medicine and Anti-EGFR Antibody Therapy in the Treatment of Metastatic Colorectal Cancer: KRAS and Beyond
    Chu, Edward
    ONCOLOGY-NEW YORK, 2014, 28 (02): : 96 - 96
  • [34] Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer
    Eide, Peter W.
    Moosavi, Seyed H.
    Eilertsen, Ina A.
    Brunsell, Tuva H.
    Langerud, Jonas
    Berg, Kaja C. G.
    Rosok, Bard I.
    Bjornbeth, Bjorn A.
    Nesbakken, Arild
    Lothe, Ragnhild A.
    Sveen, Anita
    NPJ GENOMIC MEDICINE, 2021, 6 (01)
  • [35] Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer
    Peter W. Eide
    Seyed H. Moosavi
    Ina A. Eilertsen
    Tuva H. Brunsell
    Jonas Langerud
    Kaja C. G. Berg
    Bård I. Røsok
    Bjørn A. Bjørnbeth
    Arild Nesbakken
    Ragnhild A. Lothe
    Anita Sveen
    npj Genomic Medicine, 6
  • [36] Economic analysis of biomarker-based anti-EGFR therapies in metastatic colorectal cancer in the Austrian context
    Niedersüß-Beke D.
    Simon J.
    Schiffinger M.
    Mader R.M.
    memo - Magazine of European Medical Oncology, 2018, 11 (4) : 322 - 329
  • [37] Telomere length: A novel biomarker for anti-EGFR therapy in colorectal cancer
    Augustine, Titto A.
    Baig, Mahadi A.
    Mariadason, John M.
    Maitra, Radhashree
    Goel, Sanjay
    CANCER RESEARCH, 2014, 74 (19)
  • [38] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    Rowland, A.
    Dias, M. M.
    Wiese, M. D.
    Kichenadasse, G.
    McKinnon, R. A.
    Karapetis, C. S.
    Sorich, M. J.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1888 - 1894
  • [39] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    A Rowland
    M M Dias
    M D Wiese
    G Kichenadasse
    R A McKinnon
    C S Karapetis
    M J Sorich
    British Journal of Cancer, 2015, 112 : 1888 - 1894
  • [40] Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).
    Yamazaki, Kentaro
    Yoshino, Takayuki
    Tsuchihara, Katsuya
    Shinozaki, Eiji
    Muro, Kei
    Nishina, Tomohiro
    Yamaguchi, Kensei
    Akagi, Kiwamu
    Yuki, Satoshi
    Yamanaka, Takeharu
    Nomura, Shogo
    Fujii, Satoshi
    Esumi, Hiroyasu
    Abe, Yukiko
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345